Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 10, 2026 | −$0.94 | — | $10.18M | +1041.4% | −$1.19 |
| Q1 FY26ended Mar 31, 2026 | May 11, 2026 | −$1.28 | — | $1.46M | +68.6% | −$1.22 |
| Q4 FY25ended Dec 31, 2025 | — | −$1.37 | — | $864.00K | −97.6% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$1.17 | — | $889.00K | +47.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$2.40 | — | $892.00K | +72.5% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$1.58 | — | $865.00K | +71.6% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.44 | −139.3% | $35.69M | −82.3% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$1.01 | — | $602.00K | — | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe CRISPR Therapeutics shares, not any token. As of Aug 10, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$1.49 |
| — |
| $517.00K |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$1.43 | — | $504.00K | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.12 | — | $201.21M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.41 | — | — | — | — |